A. C. Santos

TL;DR: These studies have confirmed that the approximately four times higher relaxivity measured in vitro for the metallostar is retained under in vivo conditions.

TL;DR: These NMR results show the presence of a 1:1 Ga(NOTP)3- complex, with a highly symmetrical, pseudo-octahedral geometry, possibly with a C3 axis, which agrees well with previous results from biodistribution and gamma imaging studies in Wistar rats with 67Ga3+ chelates of triaza macrocyclic ligands.

TL;DR: In vitro experiments demonstrated that GdDOTP5−-induced changes in relaxivity were silenced upon HA binding but could be recovered by acid elution of the complex, suggesting a novel strategy for creating highly sensitive, switchable MRI contrast agents.

TL;DR: It is demonstrated that the valency increase improves the targeting capability of the glycoconjugates, which is also affected by their topology, and despite the specific liver uptake of the radiolabeled galactose-bearing multivalent compounds, the animal MRI assessment of the corresponding Gd(3+) chelates shows liver-to-kidney contrast effects which are not significantly better than those shown by GdDTPA.

TL;DR: Two studies used multilevel modelling to examine optimised peak power (PPopt) from a force velocity test over the age range 12–14 years and demonstrated TMV to be a significant additional explanatory variable alongside body mass and stature with neither age nor gender making a significant contribution to PPopt.